The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine

Brain Research

Volumn 867, Issue 1-2, 2000, Pages 239-242

  Richtand, Neil M ^a,b   Logue, Aaron D ^a,b   Welge, Jeffrey A ^b   Perdiue, John ^a,b   Tubbs, Lamont J ^a,b   Spitzer, Rebecca H ^a,b   Sethuraman, Gopalan ^b   Geracioti, Thomas D ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Amphetamine; Behavioral sensitization; Dopamine D3 receptor; Nafadotride; Psychosis; Stimulant drugs

Indexed keywords

AMPHETAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; NAFADOTRIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG RECEPTOR BINDING; LOCOMOTION; MALE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; SENSITIZATION;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; LOCOMOTION; MALE; NAPHTHALENES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TETRAHYDRONAPHTHALENES;

EID: 0034625565     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)02247-2     Document Type: Article

References (24)

1. Clifford J.J., Waddington J.L. Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach. Psychopharmacology (Berl.). 136:1998;284-290.
2. Crowder M.J., Hand D.J. Analysis of Repeated Measures. 1990;Chapman and Hall, London.
3. Deminiere J.M., Piazza P.V., Guegan G., Abrous N., Maccari S., Le Moal M., Simon H. Increased locomotor response to novelty and propensity to intravenous amphetamine self-administration in adult offspring of stressed mothers. Brain Res. 586:1992;135-139.
4. Diggle P.J., Liang K.Y., Zeger S.L. Analysis of Longitudinal Data. 1994;Oxford University Press, Oxford.
5. 3H]spiperone binding. Naunyn Schmiedeberg's Arch. Pharmacol. 358:1998;342-350.
6. Flores G., Barbeau D., Quirion R., Srivastava L.K. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J. Neurosci. 16:1996;2020-2026.
7. Goldstein M., Deutch A.Y. Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J. 6:1992;2413-2421.
8. Henry C., Guegant G., Cador M., Arnauld E., Arsaut J., Le Moal M., Demotes-Mainard J. Prenatal stress in rats facilitates amphetamine-induced sensitization and induces long-lasting changes in dopamine receptors in the nucleus accumbens. Brain Res. 685:1995;179-186.
9. Hondo H., Spitzer R.H., Grinius B., Richtand N.M. Quantification of dopamine D3 receptor mRNA level associated with the development of amphetamine-induced behavioral sensitization in the rat brain. Neurosci. Lett. 264:1999;69-72.
10. Jimerson D.C. Role of dopamine mechanisms in the affective disorders. Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. 1987;505-511 Raven Press, New York.
11. Koob G.F., Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science. 242:1988;715-723.
12. Levant B., Vansell N.R. In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology. 17:1997;67-71.
13. Lipska B.K., Jaskiw G.E., Weinberger D.R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology. 9:1993;67-75.
14. Menalled L.B., Dziewczapolski G., Garcia M.C., Rubinstein M., Gershanik O.S. D3 receptor knockdown through antisense oligonucleotide administration supports its inhibitory role in locomotion. NeuroReport. 10:1999;3131-3136.
15. Piercey M.F., Lum J.T., Hoffmann W.E., Carlsson A., Ljung E., Svensson K. Antagonism of cocaine's pharmacological effects by the stimulant dopaminergic antagonists, (+)-AJ76 and (+)-UH232. Brain Res. 588:1992;217-222.
16. Ramsay D.S., Woods S.C. Biological consequences of drug administration: implications for acute and chronic tolerance. Psychol. Rev. 104:1997;170-193.
17. Sautel F., Griffon N., Sokoloff P., Schwartz J.C., Launay C., Simon P., Costentin J., Schoenfelder A., Garrido F., Mann A. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 275:1995;1239-1246.
18. Segal D.S., Kuczenski R. Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates. J. Pharmacol. Exp. Ther. 242:1987;917-926.
19. Sokoloff P., Martres M.P., Giros B., Bouthenet M.L., Schwartz J.C. The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem. Pharmacol. 43:1992;659-666.
20. Wallace D.R., Mactutus C.F., Booze R.M. Repeated intravenous cocaine administration: locomotor activity and dopamine D2/D3 receptors. Synapse. 23:1996;152-163.
21. Waters N., Svensson K., Haadsma-Svensson S.R., Smith M.W., Carlsson A. The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J. Neural Transm. Gen. Sect. 94:1993;11-19.
22. Xu M., Koeltzow T.E., Cooper D.C., Tonegawa S., White F.J. Dopamine D3 receptor mutant and wild-type mice exhibit identical responses to putative D3 receptor-selective agonists and antagonists. Synapse. 31:1999;210-215.
23. Xu M., Koeltzow T.E., Santiago G.T., Moratalla R., Cooper D.C., Hu X.T., White N.M., Graybiel A.M., White F.J., Tonegawa S. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron. 19:1997;837-848.
24. Zetterstrom T., Sharp T., Marsden C.A., Ungerstedt U. In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. J. Neurochem. 41:1983;1769-1773.